Vergent Bioscience

About Vergent Bioscience

Vergent Bioscience Inc. is a clinical-stage biotechnology firm, operating from Minneapolis, MN, aimed at enhancing the precision of cancer surgery. Founded in 2013, the company is developing molecular imaging probes that allow surgeons to better visualize and consequently remove cancerous tissue more effectively. The company's President and CEO, John Santini, Ph.D., is a serial entrepreneur with a background in creating businesses focused on pharmaceuticals, drug delivery systems, and biosensors. His experience includes leadership roles at several healthcare startups and raising significant venture capital. Santini's academic credentials include a Ph.D. in chemical engineering from MIT and a BSE from the University of Michigan, providing a strong scientific foundation for the company's endeavors.

The company's business model centers on the development and commercialization of its lead investigational product, abenacianine for injection (VGT-309). Vergent Bioscience addresses a critical need in the surgical oncology market, particularly with the rise of minimally invasive and robotic-assisted surgeries where tactile feedback is limited. Its clients are surgeons and hospitals performing these procedures. The company generates value by creating a technology that could improve surgical outcomes, potentially reducing the likelihood of leaving cancerous tissue behind. Vergent has secured substantial funding through multiple rounds, including a $21.5 million Series B financing in 2022 led by Orlando Health Ventures and including investors like Intuitive Surgical. To date, the company has raised a total of $38.4 million.

Vergent's core product, VGT-309, is a tumor-targeted fluorescent imaging agent. Delivered via a short infusion hours before an operation, it is designed to make tumors glow under near-infrared (NIR) light. The agent works by targeting cathepsins, a family of protease enzymes that are overexpressed in a wide range of solid tumors compared to healthy tissue. Once VGT-309 binds to these enzymes, its fluorescent component, which uses the NIR dye indocyanine green (ICG), is activated. This process provides a clear, real-time visual guide for surgeons, compatible with commercially available NIR imaging systems used in robotic and minimally invasive surgeries. Phase 2 clinical trials have shown VGT-309 to be safe and effective in visualizing lung tumors. In January 2025, the U.S. FDA granted Fast Track designation for VGT-309 for use in lung cancer surgery, a move that could expedite its path to market. The company is initially focused on lung cancer but plans to expand VGT-309's application to other solid tumors like colorectal, breast, and ovarian cancers.